OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Cancer is 103. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Correction to: The function and mechanisms of action of circular RNAs in Urologic Cancer	1764
SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers	940
The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments	909
Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy	810
E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer	765
Development and validation of a small extracellular vesicle-derived RNA signature for early diagnosis of lung adenocarcinoma and prognosis in advanced stages	692
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway	620
ERK mediates interferon gamma-induced melanoma cell death	583
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research	550
The puppet master in the breast cancer “microecological community”: spatial and metabolic regulation of macrophage heterogeneity	486
TGF-β signaling promotes cervical cancer metastasis via CDR1as	429
Retraction Note: Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance	402
BRD9-p53-E2F1 circuit orchestrates cell growth and DNA damage repair in gastric cancer	382
Immunotherapies in rare cancers	364
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression	333
Spatial and functional dissection of cancer-associated fibroblasts-mediated immune modulation in H. pylori-associated gastric cancer	320
Correction: m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC	317
Engineered multifunctional nanoparticles for enhanced radiation therapy: three-in-one approach for cancer treatment	301
Neoadjuvant immunotherapy in squamous cell carcinoma of the head and neck: current evidence and future perspectives	292
LMTK3 regulation of EV biogenesis and cargo sorting promotes tumour growth by reducing monocyte infiltration and driving pro-tumourigenic macrophage polarisation in breast cancer	289
Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma	281
Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers	266
Tumor microenvironment dynamics in gastric cancer pathogenesis and therapeutic resistance	263
The epigenetic regulatory mechanism of PIWI/piRNAs in human cancers	252
LINC02159 promotes non-small cell lung cancer progression via ALYREF/YAP1 signaling	248

Exosomal circSIPA1L3-mediated intercellular communication contributes to glucose metabolic reprogramming and progression of triple negative breast cancer	242
The miR-23a/27a/24 − 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer	236
circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP/IL-6 axis	232
KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers	229
Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications	228
Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells	219
Chaperone-mediated autophagy modulates Snail protein stability: implications for breast cancer metastasis	213
Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery	212
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers	211
Increased plasma concentrations of acyl-coenzyme A binding protein (ACBP) predict future lung cancer development in smokers at risk of cardiovascular disease	211
LncRNA PVT1 in human cancers: genomic complexity, isoforms, functional elements, mechanism of action, subcellular localization and possible role as a therapeutic target	209
Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection	203
Effects of RNA methylation on Tumor angiogenesis and cancer progression	203
Nanotechnology-leveraged CRISPR/Cas systems: icebreaking in trace cancer-related nucleic acids biosensing	201
Bidirectional role of neutrophils in tumor development	200
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state	196
Efferocytosis: the art of cellular clearance and novel perspectives in disease therapy	191
Biofilm formation by the host microbiota: a protective shield against immunity and its implication in cancer	191
Biomarker-empowered precision navigation of CAR-T cell therapy	189
LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling	189
AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemia	188
Biomolecular phase separation in tumorigenesis: from aberrant condensates to therapeutic vulnerabilities	183
Nuclear receptors as novel regulators that modulate cancer radiosensitivity and normal tissue radiotoxicity	179
Correction: Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis	178
Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment	177
Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer	172
NK cells are never alone: crosstalk and communication in tumour microenvironments	170
Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside	166
Context-dependent effect of glucocorticoid receptor activity shapes ovarian cancer cell plasticity and therapy response	166
Myofibroblast-derived extracellular vesicles facilitate cancer stemness of hepatocellular carcinoma via transferring ITGA5 to tumor cells	164
Tumor cell-intrinsic MELK enhanced CCL2-dependent immunosuppression to exacerbate hepatocarcinogenesis and confer resistance of HCC to radiotherapy	162
Emerging roles of tRNA-derived fragments in cancer	161
Therapy-induced senescent tumor cell-derived extracellular vesicles promote colorectal cancer progression through SERPINE1-mediated NF-κB p65 nuclear translocation	160
Gold nanoparticles and gold nanorods in the landscape of cancer therapy	160
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes	159
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments	157
Correction: The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC	154
Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy	153
Dissecting small cell carcinoma of the esophagus ecosystem by single-cell transcriptomic analysis	152
Circular RNA circCLASP2 promotes nasopharyngeal carcinoma progression through binding to DHX9 to enhance PCMT1 translation	152
Targeting cholesterol-driven immunometabolism in cancer: from molecular circuits to clinical translation	150
Metabolic reprogramming and molecular crosstalk at the cancer–endothelial interface in ovarian carcinoma	150
Loss of TACC2 impairs chemokine CCL3 and CCL4 expression and reduces response to anti-PD-1 therapy in soft tissue sarcoma	149
Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition	149
Deubiquitination of CDC6 by OTUD6A promotes tumour progression and chemoresistance	147
Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy	146
Correction: Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1	143
Correction: Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis	141
Retraction Note: Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis	140
Biologically targeted dual adaptive and innate nano-Immunotherapy for clear cell renal cell carcinoma treatment	138

The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer	138
lncRNAs: the unexpected link between protein synthesis and cancer adaptation	138
Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells	136
Correction: CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling	135
EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin?	134
Modeling pediatric low-grade glioma heterogeneity using human forebrain organoids	131
A positive feedback loop between PFKP and c-Myc drives head and neck squamous cell carcinoma progression	129
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy	126
Exosome circATP8A1 induces macrophage M2 polarization by regulating the miR-1-3p/STAT6 axis to promote gastric cancer progression	125
The application of organoids in treatment decision-making for digestive system cancers: progress and challenges	123
CircAKT3 promotes prostate cancer proliferation and metastasis by enhancing the binding of RPS27A and RPL11	122
Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors	120
Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies	119
Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer	118
m6A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma	118
Context-dependent impact of type I interferon signaling in cancer	118
Neuroscience of cancer: unraveling the complex interplay between the nervous system, the tumor and the tumor immune microenvironment	117
Activation-induced cytidine deaminase causes recurrent splicing mutations in diffuse large B-cell lymphoma	114
Molecular mechanisms of tumor resistance to radiotherapy	114
CDC6 is a prognostic biomarker and correlated with immune infiltrates in glioma	114
Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response	113
Correction: Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy	111
Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL	109
Correction: MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer	109
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors	108
Retraction Note: Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer	106
Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age	105
Cancer neuroscience in head and neck: interactions, modulation, and therapeutic strategies	105